Reading ROIV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ROIV free→Reading ROIV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ROIV free→
NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and management's recent track record has been steady. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is moderate, and the sector backdrop is a headwind, which may impact future performance. If ROIV cuts guidance on the next call, that could be a meaningful negative. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $30.41. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 2.50x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
3 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.33 → $-0.36 (-6.7% / 30d). 0 raised, 2 cut, 3 covering analysts.
0 upgrades, 0 downgrades / 30d, 4 maintained. 92% of analysts rate Buy.
3 PT revisions / 30d. Avg target 25.7% above current price.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$143.
How much price usually moves either way.
On a bad day, this stock has moved -$294.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,284.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Achieving positive net income is a key goal for Roivant. It shows financial health.
Confirms:Net income reported as positive in the next earnings release.
Disproves:Net income remains negative in the next earnings release.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ROIV yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition” (including Exhibit 99.1) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ROIV Roivant Sciences | Typical Show detailsSector percentile: 66 of 100 | — | moderate |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 81 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 99 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Roivant plans to commercially launch brepocitinib for dermatomyositis by the end of September 2026.
Roivant will provide further updates on the IMVT-1402 trial in difficult-to-treat rheumatoid arthritis in the second half of 2026.
Roivant aims to maintain positive net income, as evidenced by recent financial results.
Focus on increasing operating income through cost management and revenue growth.
Enhance cash flow from operating activities through better cost control and efficiency.
Why it matters: Higher operating income shows Roivant can control costs and grow.
Confirms:Operating income is above $415.2M in the next earnings release.
Disproves:Operating income is below $415.2M in the next earnings release.
Why it matters: If sector growth slows, it could hurt Roivant's performance and outlook.
Confirms:Sector revenue growth reported below its median in the next quarter.
Disproves:Sector revenue growth remains above its median in the next quarter.
Why it matters: Updates may show if IMVT-1402 works for hard-to-treat rheumatoid arthritis.
Confirms:Positive updates on IMVT-1402 trial results are shared in the second half of 2026.
Disproves:No updates or negative results from the IMVT-1402 trial are reported.
Why it matters: Better cash flow from operations is key for Roivant's financial health.
Confirms:Cash from operations is less negative than -$163.8M in the next earnings release.
Disproves:Cash from operations is more negative than -$163.8M in the next earnings release.
Why it matters: Updates on cash will show if Roivant can keep running until it makes money.
Confirms:Roivant says it has enough cash to keep running until it makes money.
Disproves:Cash position drops a lot, raising worries about staying in business.
Results of Operations and Financial Condition On April 2, 2026, Roivant Sciences Ltd. (the “Company”) announced preliminary unaudited consolidated cash, cash equivalents and marketable securities as of March 31, 2026 of approximately $4.3 billion. For the three months ended March 31, 2026, the Company repurchased 3,956,362 common shares for an aggregate purchase price of approximately $109.7 million (excluding fees and commission). The information in this
of the Original 8-K is hereby incorporated by reference. As described in the Original 8-K, on March 3, 2026, Genevant, Arbutus and, solely for certain purposes, GSL, entered into a Settlement Agreement with Moderna to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna's use of Genevant/Arbutus’ lipid nanoparticle delivery technology in its vaccines. The foregoing description of the Settlement Agreement do…
Entry into a Material Definitive Agreement On March 3, 2026 (the “Effective Date”), Genevant Sciences GmbH (“Genevant”), a subsidiary of Roivant Sciences Ltd. (the “Company” or “Roivant”), Arbutus Biopharma Corp. (together with Genevant, “Genevant/Arbutus”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between G…
Other Information On March 3, 2026, Roivant’s board of directors authorized an increase in the size of the previously approved common share repurchase program allowing for repurchases of the Company’s common shares in an aggregate amount of up to $1.0 billion (excluding fees and expenses), inclusive of the previously announced $500 million repurchase authorization. The repurchase program will be funded with available cash and cash equivalents on hand and does not have an expiration date. The…